loader from loading.io

Addressing Health Disparities Through Workforce Diversity and Improved Access to Clinical Trials with Dr. Eugene Manley STEMM & Cancer Health Equity Foundation TRANSCRIPT

Empowered Patient Podcast

Release Date: 01/21/2026

Driving Innovation in Cell Therapy Manufacturing  with Ryan Clarke Syntax Bio TRANSCRIPT show art Driving Innovation in Cell Therapy Manufacturing with Ryan Clarke Syntax Bio TRANSCRIPT

Empowered Patient Podcast

 Ryan Clarke, Co-Founder and CTO of Syntax Bio, is focused on solving manufacturing challenges in producing stem cell-derived therapies, specifically the process of stem cell differentiation. The Cellgorithm platform was designed to make differentiation an engineering problem by using a modified form of CRISPR to turn genes on and off in a specific, controlled sequence, reducing processing time from months to days and resulting in cost savings. One goal is to use AI and machine learning to build models capable of predicting optimal gene regulation sequences accelerating the discovery of...

info_outline
Driving Innovation in Cell Therapy Manufacturing  with Ryan Clarke Syntax Bio show art Driving Innovation in Cell Therapy Manufacturing with Ryan Clarke Syntax Bio

Empowered Patient Podcast

 Ryan Clarke, Co-Founder and CTO of Syntax Bio, is focused on solving manufacturing challenges in producing stem cell-derived therapies, specifically the process of stem cell differentiation. The Cellgorithm platform was designed to make differentiation an engineering problem by using a modified form of CRISPR to turn genes on and off in a specific, controlled sequence, reducing processing time from months to days and resulting in cost savings. One goal is to use AI and machine learning to build models capable of predicting optimal gene regulation sequences accelerating the discovery of...

info_outline
Origins and Future of Medical Imaging with Dr. David Sodickson Function Health TRANSCRIPT show art Origins and Future of Medical Imaging with Dr. David Sodickson Function Health TRANSCRIPT

Empowered Patient Podcast

Dr. Daniel Sodickson is Chief Medical Scientist at Function Health and author of the new book, The Future of Seeing: How Imaging Is Changing Our World. Building on the drive to improve medical imaging, AI and neural networks are now reshaping image interpretation and how and what data are collected. This approach produces high-quality results with minimal additional data and is inspiring innovative scanning techniques and equipment design. The future of medical imaging is the everywhere scanner, enhancing a single-shot session with a large hospital machine with continuous health...

info_outline
Origins and Future of Medical Imaging with Dr. David Sodickson Function Health show art Origins and Future of Medical Imaging with Dr. David Sodickson Function Health

Empowered Patient Podcast

Dr. Daniel Sodickson is Chief Medical Scientist at Function Health and author of the new book, The Future of Seeing: How Imaging Is Changing Our World. Building on the drive to improve medical imaging, AI and neural networks are now reshaping image interpretation and how and what data are collected. This approach produces high-quality results with minimal additional data and is inspiring innovative scanning techniques and equipment design. The future of medical imaging is the everywhere scanner, enhancing a single-shot session with a large hospital machine with continuous health...

info_outline
Stem Cell Therapy Aims to Rebuild Brain Circuits in Parkinson’s Patients with Dr. Howard Federoff Kenai Therapeutics TRANSCRIPT show art Stem Cell Therapy Aims to Rebuild Brain Circuits in Parkinson’s Patients with Dr. Howard Federoff Kenai Therapeutics TRANSCRIPT

Empowered Patient Podcast

Dr. Howard Federoff, Scientific Co-Founder, Chief Medical Officer, and Executive Vice President of Corporate Medicine and Science at Kenai Therapeutics, is developing a cell therapy for Parkinson's disease that involves transplanting IPSCs into the brain to replace lost dopamine neurons.  The goal is not to cure the underlying cause of the disease, but to restore motor function and reverse the disease's progression. Initial clinical focus was on patients with moderate to moderate-severe idiopathic Parkinson's, showing efficacy and safety, leading to expanding the study to include...

info_outline
Stem Cell Therapy Aims to Rebuild Brain Circuits in Parkinson’s Patients with Dr. Howard Federoff Kenai Therapeutics show art Stem Cell Therapy Aims to Rebuild Brain Circuits in Parkinson’s Patients with Dr. Howard Federoff Kenai Therapeutics

Empowered Patient Podcast

Dr. Howard Federoff, Scientific Co-Founder, Chief Medical Officer, and Executive Vice President of Corporate Medicine and Science at Kenai Therapeutics, is developing a cell therapy for Parkinson's disease that involves transplanting IPSCs into the brain to replace lost dopamine neurons.  The goal is not to cure the underlying cause of the disease, but to restore motor function and reverse the disease's progression. Initial clinical focus was on patients with moderate to moderate-severe idiopathic Parkinson's, showing efficacy and safety, leading to expanding the study to include...

info_outline
Transforming MRI Data to Identify Biomarkers for Diagnosing and Treating Back Pain with Brent Ness Aclarion TRANSCRIPT show art Transforming MRI Data to Identify Biomarkers for Diagnosing and Treating Back Pain with Brent Ness Aclarion TRANSCRIPT

Empowered Patient Podcast

Brent Ness, CEO and President of Aclarion,  highlights the challenges of diagnosing and treating chronic lower back pain, a leading driver of healthcare costs and opioid addiction. Traditional MRI and CT imaging do not reveal the biochemical source of pain within spinal discs, leading to misdiagnosis and unsuccessful treatment. The Aclarion technology uses MR spectroscopy to measure pain-causing biomarkers and, through a cloud-based, AI-powered SaaS model, analyzes the raw data and sends the physician a report within minutes. Brent explains, "The diagnosis and accurate treatment planning...

info_outline
Transforming MRI Data to Identify Biomarkers for Diagnosing and Treating Back Pain with Brent Ness Aclarion show art Transforming MRI Data to Identify Biomarkers for Diagnosing and Treating Back Pain with Brent Ness Aclarion

Empowered Patient Podcast

Brent Ness, CEO and President of Aclarion,  highlights the challenges of diagnosing and treating chronic lower back pain, a leading driver of healthcare costs and opioid addiction. Traditional MRI and CT imaging do not reveal the biochemical source of pain within spinal discs, leading to misdiagnosis and unsuccessful treatment. The Aclarion technology uses MR spectroscopy to measure pain-causing biomarkers and, through a cloud-based, AI-powered SaaS model, analyzes the raw data and sends the physician a report within minutes. Brent explains, "The diagnosis and accurate treatment planning...

info_outline
First Non-Steroidal MRA Drug Approved for Heart Failure with Dr. Alanna Morris-Simon Bayer TRANSCRIPT show art First Non-Steroidal MRA Drug Approved for Heart Failure with Dr. Alanna Morris-Simon Bayer TRANSCRIPT

Empowered Patient Podcast

Dr. Alanna Morris-Simon, Senior Medical Director for US Medical Affairs at Bayer, describes the symptoms and diagnostics used to classify heart failure and the key at-risk populations for this condition. The rapidly evolving landscape of heart failure treatments now includes the Bayer drug KERENDIA, a non-steroidal MRA approved to reduce cardiovascular death and heart failure in adults with an ejection fraction of 40% or more. This drug is part of an emerging trend to treat multiple related conditions simultaneously  and could prevent the onset of heart failure and treat established...

info_outline
First Non-Steroidal MRA Drug Approved for Heart Failure with Dr. Alanna Morris-Simon Bayer show art First Non-Steroidal MRA Drug Approved for Heart Failure with Dr. Alanna Morris-Simon Bayer

Empowered Patient Podcast

Dr. Alanna Morris-Simon, Senior Medical Director for US Medical Affairs at Bayer, describes the symptoms and diagnostics used to classify heart failure and the key at-risk populations for this condition. The rapidly evolving landscape of heart failure treatments now includes the Bayer drug KERENDIA, a non-steroidal MRA approved to reduce cardiovascular death and heart failure in adults with an ejection fraction of 40% or more. This drug is part of an emerging trend to treat multiple related conditions simultaneously  and could prevent the onset of heart failure and treat established...

info_outline
 
More Episodes

Dr. Eugene Manley, biomedical scientist turned social impact leader and Founder and CEO of the STEMM & Cancer Health Equity Foundation,  is focused on increasing STEMM workforce diversity and improving outcomes for underserved cancer patients. He highlights the lack of diversity in foundational lung cancer research and the need to expand the number of cell lines being included to develop more effective therapies. Eugene also raises concerns about barriers to clinical trial participation and the need to engage local community partners and AI to raise awareness and improve accessibility.

Eugene explains, "The SCHEQ Foundation, which is a short name for STEMM and Cancer Health Equity, is tasked with working to increase STEMM workforce diversity and improve outcomes for underserved patients navigating the cancer care continuum. This is done broadly through trying to increase STEMM access and exposure, mentorship and training programs to help students navigate career transitions, and providing information and resources to underserved patients to help them navigate and access the care they're entitled to."

"There are many paths into the medical field now. If you're trying to do particularly applied research or do things that directly impact patient outcomes, then yes, you might want to go more of a technical path. But as we mentioned, AI is the new thing on the block. It's a lot of looking at trends, variances, and differences in data, and then you can use that to predict how things may act or behave. However, the downside of this is that the data is often based on one population, one race, or ethnicity, which makes it harder to broadly generalize these results. So that's a lot of the challenges that we're seeing right now."

#SCHEQ #HealthEquity #STEMM #CancerResearch #DiversityInScience #BiomedicalResearch #ClinicalTrials #LungCancer #HealthDisparities #MedicalInnovation #SocialImpact #HealthcareAccess #PrecisionMedicine

scheq.org

Listen to the podcast here

 

SCHEQ